Oramed says Phase 2a ORMD-0801 study met all primary, secondary endpoints Oramed Pharmaceuticals announced results from its Phase 2a clinical trial for its ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes. The trial was conducted under a United States FDA Investigational New Drug protocol. The Phase 2a study met all primary and secondary endpoints. 30 patients with type 2 diabetes took part in the trial in an in-patient setting for one week. Endpoints of safety as well as pharmacodynamic and pharmacokinetic effects were evaluated against a placebo control. For full information on the Phase 2a trial design and endpoints please see Clinical Trials. Full results are expected to be presented at a scientific conference in the future. "We are extremely pleased with the results which give a solid validation for Oramed's platform technology in general and our oral insulin program in particular," stated Oramed CEO Nadav Kidron. "Following on the results from this type 2 diabetes study we are gearing up to start a multi-center Phase 2b study later this year. We are also excited about the potential of this drug for type 1 diabetes and plan to initiate a Phase 2a FDA study for this indication in the near term."